Temozolomide in the treatment of solid tumours: Current results and rationale for dosing/scheduling

Critical Reviews in Oncology/Hematology

Volumn 53, Issue 3, 2005, Pages 241-252

  Payne, M J ^a   Pratap, S E ^a   Middleton, M R ^a,b,c  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; Schedule; Temozolomide

Indexed keywords

DACARBAZINE; DNA TOPOISOMERASE INHIBITOR; INTERFERON; IRINOTECAN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PROCARBAZINE; SEROTONIN 3 ANTAGONIST; TEMOZOLOMIDE; THALIDOMIDE;

ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ASTHENIA; ASTROCYTOMA; BLOOD BRAIN BARRIER; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN METASTASIS; BRAIN TUMOR; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; CONSTIPATION; CYTOTOXICITY; DNA METHYLATION; DNA REPAIR; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; ENZYME INHIBITION; EXCISION REPAIR; FATIGUE; FEVER; HEADACHE; HUMAN; IMMUNOTHERAPY; KIDNEY CARCINOMA; LEIOMYOSARCOMA; LYMPHOCYTOPENIA; MELANOMA; METASTASIS; MISMATCH REPAIR; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; OPPORTUNISTIC INFECTION; PAIN; QUALITY OF LIFE; REVIEW; SOFT TISSUE SARCOMA; SOLID TUMOR; THROMBOCYTOPENIA; TISSUE DISTRIBUTION; VOMITING;

EID: 13844254498     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2004.10.004     Document Type: Review

References (66)

1. M. Brada NICE verdict on temozolomide: where next? Br J Cancer 86 4 2002 499 500
2. D.K. Park, C.W. Ryan, M.E. Dolan, N.J. Vogelzang, and W.M. Stadler A phase II trial of oral temozolomide in patients with metastatic renal cell cancer Cancer Chemother Pharmacol 50 2 2002 160 162
3. S.M. Talbot, M.L. Keohan, and M. Hesdorffer A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma Cancer 98 9 2003 1942 1946
4. M.J. Moore, R. Feld, D. Hedley, A. Oza, and L.L. Siu A phase II study of temozolomide in advanced untreated pancreatic cancer Invest New Drugs 16 1 1998 77 79
5. A.T. Chan, T.W. Leung, and W.H. Kwan Phase II study of temodal in the treatment of patients with advanced nasopharyngeal carcinoma Cancer Chemother Pharmacol 42 3 1998 247 249
6. J.P. van Brussel, M.B. Busstra, M.S. Lang, T. Catsburg, F.H. Schroder, and G.H. Mickisch A phase II study of temozolomide in hormone-refractory prostate cancer Cancer Chemother Pharmacol 45 6 2000 509 512
7. L.E. Abrey, and C. Christodoulou Temozolomide for treating brain metastases Semin Oncol 28 4 Suppl 13 2001 34 42
8. C. Marzolini, L.A. Decosterd, and F. Shen Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration Cancer Chemother Pharmacol 42 6 1998 433 440
9. M. Patel, C. McCully, K. Godwin, and F.M. Balis Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates J Neurooncol 61 3 2003 203 207
10. J. Plowman, W.R. Waud, A.D. Koutsoukos, L.V. Rubinstein, T.D. Moore, and M.R. Grever Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)- 1-nitrosourea Cancer Res 54 14 1994 3793 3799
11. M.F. Stevens, J.A. Hickman, and S.P. Langdon Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5- tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine Cancer Res 47 22 1987 5846 5852
12. H.S. Friedman, M.E. Dolan, and A.E. Pegg Activity of temozolomide in the treatment of central nervous system tumor xenografts Cancer Res 55 13 1995 2853 2857
13. 6-methylguanine formation, repair protein depletion and clinical outcome with a 4-h schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study Int J Cancer 88 2000 469 473
14. E.S. Newlands, G.R. Blackledge, and J.A. Slack Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856) Br J Cancer 65 2 1992 287 291
15. N.M. Bleehen, E.S. Newlands, and S.M. Lee Cancer research campaign phase II trial of temozolomide in metastatic melanoma J Clin Oncol 13 4 1995 910 913
16. M.R. Middleton, J.J. Grob, and N. Aaronson Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma J Clin Oncol 18 1 2000 158 166
17. S.M. O'Reilly, E.S. Newlands, and M.G. Glaser Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours Eur J Cancer 29 A 7 1993 940 942
18. E.S. Newlands, S.M. O'Reilly, and M.G. Glaser The Charing Cross Hospital experience with temozolomide in patients with gliomas Eur J Cancer 32 A 13 1996 2236 2241
19. M. Bower, E.S. Newlands, and N.M. Bleehen Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma Cancer Chemother Pharmacol 40 6 1997 484 488
20. W.K. Yung, R.E. Albright, and J. Olson A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse Br J Cancer 83 5 2000 588 593
21. W.K. Yung, M.D. Prados, and R. Yaya-Tur Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group J Clin Oncol 17 9 1999 2762 2771
22. A.A. Brandes, M. Ermani, and U. Basso Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study Ann Oncol 12 2 2001 255 257
23. B.L. Ebert, E. Niemierko, K. Shaffer, and R. Salgia Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer Oncologist 8 1 2003 69 75
24. R. Dziadziuszko, A. Ardizzoni, and P.E. Postmus Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. A phase II study of the EORTC Lung Cancer Group (08965) Eur J Cancer 39 9 2003 1271 1276
25. S. Villa, E. Verger, and M. Gil Concomitant and adjuvant temozolomide (TMZ) and whole brain irradiation (WBI) on patients affected with brain metastases (BM): a randomized multicentric phase II trial Int J Radiat Oncol Biol Phys 57 2 Suppl 2003 S132
26. Summers Y, Middleton M, Calvert H, Siow L, Rustin G, Newell D, et al. Effect of temozolomide (TMZ) on central nervous system (CNS). Relapse in patients with advanced melanoma (meeting abstract); 1999. p. ab 2048.
27. S.S. Agarwala, J.M. Kirkwood, and M. Gore Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study J Clin Oncol 22 11 2004 2101 2107
28. A. Saleem, G.D. Brown, and F. Brady Metabolic activation of temozolomide measured in vivo using positron emission tomography Cancer Res 63 10 2003 2409 2415
29. B.J. Denny, R.T. Wheelhouse, M.F. Stevens, L.L. Tsang, and J.A. Slack NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA Biochemistry 33 31 1994 9045 9051
30. S. D'Atri, L. Tentori, and P.M. Lacal Involvement of the mismatch repair system in temozolomide-induced apoptosis Mol Pharmacol 54 2 1998 334 341
31. S.L. Gerson Clinical relevance of MGMT in the treatment of cancer J Clin Oncol 20 9 2002 2388 2399
32. 6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents Cancer Res 50 19 1990 6119 6129
33. 6-methylguanine-DNA methyltransferase activity in human tumors Carcinogenesis 13 9 1992 1503 1507
34. 6-alkylguanine-DNA alkyltransferase expression in normal and malignant human colon Clin Cancer Res 2 3 1996 577 584
35. 6-alkylguanine DNA-alkyltransferase in human liver and melanoma Br J Cancer 66 2 1992 355 360
36. 6-methylguanine-DNA methyltransferase in the resistance of pancreatic tumors to DNA alkylating agents Cancer Res 57 23 1997 5360 5368
37. 6-methylguanine-DNA methyltransferase in pediatric primary brain tumors: relation to patient and tumor characteristics Clin Cancer Res 7 3 2001 613 619
38. J.G. Hengstler, B. Tanner, L. Moller, R. Meinert, and B. Kaina Activity of O(6)-methylguanine-DNA methyltransferase in relation to p53 status and therapeutic response in ovarian cancer Int J Cancer 84 4 1999 388 395
39. 6-alkylguanine-DNA alkyltransferase analysis and response to temodal in newly diagnosed malignant glioma J Clin Oncol 16 12 1998 3851 3857
40. 6-methylguanine-DNA- methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma Br J Cancer 89 8 2003 1517 1523
41. O. Humbert, S. Fiumicino, and G. Aquilina Mismatch repair and differential sensitivity of mouse and human cells to methylating agents Carcinogenesis 20 2 1999 205 214
42. P. Taverna, L. Liu, A.J. Hanson, A. Monks, and S.L. Gerson Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen Cancer Chemother Pharmacol 46 6 2000 507 516
43. C.R. Calabrese, M.A. Batey, and H.D. Thomas Identification of potent nontoxic poly(ADP-ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies Clin Cancer Res 9 7 2003 2711 2718
44. M.J. Hickman, and L.D. Samson Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents Proc Natl Acad Sci USA 96 19 1999 10764 10769
45. 6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide Br J Cancer 69 3 1994 452 456
46. S. Danson, P. Lorigan, and A. Arance Randomized phase II study of temozolomide given every 8 h or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma J Clin Oncol 21 13 2003 2551 2557
47. T.P. Spiro, L. Liu, S. Majka, J. Haaga, J.K. Willson, and S.L. Gerson Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase Clin Cancer Res 7 8 2001 2309 2317
48. L.A. Hammond, J.R. Eckardt, and S.D. Baker Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies J Clin Oncol 17 8 1999 2604 2613
49. M. Dhodapkar, J. Rubin, and J.M. Reid Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer Clin Cancer Res 3 7 1997 1093 1100
50. C.S. Brock, E.S. Newlands, and S.R. Wedge Phase I trial of temozolomide using an extended continuous oral schedule Cancer Res 58 19 1998 4363 4367
51. Y.B. Su, S. Sohn, and S.E. Krown Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications J Clin Oncol 22 4 2004 610 616
52. 6-alkylguanine DNA alkyltransferase (AGAT) Eur J Cancer 37 56 2001 ab 105
53. K. Vera, L. Djafari, and S. Faivre Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors Ann Oncol 15 1 2004 161 171
54. L. Tentori, I. Portarena, E. Bonmassar, and G. Graziani Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly(ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells Cell Death Differ 8 2001 457 469
55. L. Tentori, C. Leonetti, and M. Scarsella Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma Clin Cancer Res 9 14 2003 5370 5379
56. L. Tentori, I. Portarena, and M. Barbarino Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly(ADP-ribose) polymerase inhibitor Mol Pharmacol 63 1 2003 192 202
57. 6-alkylguanine-DNA alkyltransferase activity Br J Cancer 74 7 1996 1030 1036
58. S.F. Jones, V.G. Gian, and F.A. Greco Phase I trial of irinotecan and temozolomide in patients with solid tumors Oncology (Huntingt) 17 5 Suppl 5 2003 41 45
59. E.S. Newlands, T. Foster, and S. Zaknoen Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas Br J Cancer 89 2 2003 248 251
60. W.J. Hwu, S.E. Krown, and J.H. Menell Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma J Clin Oncol 21 17 2003 3351 3356
61. E.S. Newlands, M.F. Stevens, S.R. Wedge, R.T. Wheelhouse, and C. Brock Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials Cancer Treat Rev 23 1 1997 35 61
62. R. Stupp, I. Maillard, and A. Pica Daily temozolomide (TMZ) and concomitant radiotherapy followed by adjuvant TMZ for newly diagnosed glioblastoma multiforme (GBM). A well tolerated and promising regime Proc ASCO 18 ab 592 1999 154a
63. R. Stupp, P.Y. Dietrich, and S. Ostermann Kraljevic Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide J Clin Oncol 20 5 2002 1375 1382
64. Stupp RM, Van Den Bent WM, et al. Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain and RT and NCIC clinical trials group. In: Proceedings of the ASCO Annual Meeting, J Clin Oncol 2004;22(14S):1s.
65. M.R. Gilbert, H.S. Friedman, and J.F. Kuttesch A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy Neurooncol 4 4 2002 261 267
66. 6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: Results of a Phase II study Int. J. Cancer 88 2000 469 473